Das COP9 Signalosom (CSN) ist ein hoch konservierter Proteinkomplex, der an der Regulation des Ubiquitin (Ub)-26S Proteasomsystems (UPS) beteiligt ist. Das UPS ist die wichtigste Proteolysemaschinerie in eukaryotischen Zellen, bei der Proteine über eine dreistufige Kaskade der Enzyme E1-E3 mit einer Ub-Kette markiert werden, die als Erkennungssignal für den Abbau durch das 26S Proteasom dient. Das CSN gilt als Paralog zum Lid, einem Subkomplex des 26S Proteasoms, und interagiert mit einer Vielzahl von Proteinen, unter anderem mit E3-Ligasen und Kinasen. In dieser Arbeit konnte die direkte Bindung des CSN an das 26S Proteasom gezeigt werden, was zu einem Einfluss auf die Peptidaseaktivität des 26S Proteasoms in vitro führt. In Flag-Pulldown-Experimenten aus B8 Mausfibroblasten, die stabil mit Flag-CSN2 transfiziert waren, wurde ein vollständiger Flag-CSN-Komplex nachgewiesen, der mit dem 26S Proteasom assoziiert vorliegt. Co-Immunpräzipitationen beider Komplexe in vitro wiesen auf eine konzentrationsabhängige Verdrängung des Lid-Subkomplexes durch das CSN hin. Diese Interaktion führte zur Reduktion der proteolytischen Aktivität des 26S Proteasoms. Darüber hinaus wurde eine assoziierte deubiquitinierende Aktivität am CSN entdeckt und als USP15 identifiziert. Die Charakterisierung von USP15 zeigte, dass es durch die am CSN assoziierte Kinase CK2 phosphoryliert und stabilisiert wird. Erstmalig konnte durch Inhibitorstudien mit ortho-Phenanthrolin eine Metallabhängigkeit der Aktivität von USP15 nachgewiesen werden, die zur Identifizierung eines bisher unbekannten Zn-Fingers führte. Mutationsanalysen des Zn-Fingers zeigen, dass dieser für die Bindung und Spaltung von Ub-Ketten, nicht aber von linearen Ub-Konstrukten, notwendig ist. In Zellexperimenten konnte nachgewiesen werden, dass USP15 die E3 Ligase Rbx1 stabilisiert, was vermutlich auf eine Umkehr der Autoubiquitinierung zurückzuführen ist. Das CSN scheint somit sowohl das 26S Proteasom als auch die E3-Ligasen direkt zu beeinflussen. Die Ergebnisse dieser Arbeit stellen eine Vertiefung der Erkenntnisse über das CSN als Regulator des UPS dar. / The COP9 signalosome (CSN) is a conserved protein complex that is involved in the regulation of the ubiquitin (Ub)/26S proteasome system (UPS). The UPS is the most important degradation machinery in eukaryotic cells. By the concerted action of three enzymes, E1-E3, proteins are labelled with a Ub-chain that serves as a recognition signal for the degradation by the 26S proteasome. The CSN is homologous to the lid, a subcomplex of the 26S proteasome, and interacts with numerous proteins, including E3 Ub ligases and kinases. In this study a direct interaction of the CSN with the 26S proteasome could be shown which has consequences for the peptidase activity of the 26S proteasome in vitro. In Flag-pull-down experiments from mouse B8 fibroblasts, that permanently expressed Flag-CSN2, an intact Flag-CSN complex was detected that is associated with the 26S proteasome. Co-immunoprecipitation of both complexes in vitro indicated a concentration-dependent replacement of the lid subcomplex by the CSN. This interaction led to a decrease of the proteolytic activity of the 26S proteasome. Moreover, a deubiquitinating activity associated with the CSN was discovered and identified as USP15. The USP15 was phosphorylated by the CSN-associated kinase CK2 that stabilised the enzyme. For the first time inhibitor studies with ortho-phenanthroline demonstrated a metal-dependency for the activity of USP15 that could be attributed to a formerly unidentified Zn-finger. Mutational analysis of the Zn-finger showed that it is necessary for the binding and cleavage of poly-Ub-chains but not for linear Ub-constructs. Cell culture experiments demonstrated a stabilisation of the E3 ligase Rbx1 by USP15 most likely by reversing its autoubiquitination. Therefore the CSN seems to directly influence the 26S proteasome as well as E3 ligases in their functions. These results expand the present knowledge on the CSN as a regulator of the UPS.

Im Kampf gegen eine Virusinfektion spielen CD8+ T Zellen des adaptiven Immunsystems eine besondere Rolle. Sie patroullieren im Körper und entdecken spezifische Virusepitope, welche mittels MHC Klasse I Molekülen auf der Oberfläche infizierter Zellen präsentiert werden. Wird eine virus-infizierte Zelle erkannt, kann diese schnell und effizient eliminiert. Für die Generierung viraler Peptide, welche auf MHC Klasse I Komplexe geladen werden, ist das Ubiquitin-Proteasom-System von essentieller Bedeutung. Kürzlich wurden weitere Funktionen des Immunoproteasoms aufgedeckt wie zum Beispiel der Schutz gegen oxidativen Stress. Innerhalb der vorliegenden Arbeit konnte die Fähigkeit des Immunoproteasoms gegen eine Akkumulation oxidativ geschädigter Proteine zu schützen mit der Generierung von MHC Klasse I Liganden kombiniert und neu interpretiert werden. Es konnte gezeigt werden, dass während einer Virusinfektion in Nicht-Immunzellen die Produktion reaktiver Sauerstoffspezies durch die alternative NADPH Oxidase Nox4 eine bedeutende Rolle spielt. Die Aktivierung von Nox4 resultiert in der Akkumulation oxidativ geschädigter Proteine. Innerhalb von zwei Stunden nach dem Eintreten von Viruspartikeln in die Zellen wurden strukturelle Virusproteine oxidiert und anschließend ubiquityliert. Die gleichzeitige, virus-induzierte Expression von Immunoproteasomen führte zu einem schnellen und effizienten Abbau ubiquitylierter Virusantigene. Infolgedessen konnten immundominante Virusepitope vermehrt freigesetzt werden. Folglich wurde ein soweit unbekannter Mechanismus gefunden, welcher Substrate für das Proteasom zur Generierung von MHC Klasse I Liganden bereitstellt. Zusammenfassend konnte innerhalb dieser Arbeit gezeigt werden, dass das Immunoproteasom den Schutz vor oxidativen Stress mit der Generierung antigener Peptide verbindet, wodurch eine effektive adaptive Immunantwort etabliert werden kann. / An efficient immune control of virus infection is predominantly mediated by CD8+ T cells which patrol through the body and eliminate infected cells. Infected cells are recognized when they present viral antigenic peptides on their surface via MHC class I molecules. To make antigenic peptides available for loading on MHC class I complexes, the ubiquitin proteasome system plays a crucial role. Moreover, the induction of the i-proteasome is known to support the generation of MHC class I ligands. Recently, new functions of the i-proteasome have been discovered. Evidence is increasing that the i-proteasome is involved in the protection of cells against oxidative stress. Within this thesis the characteristic of the i-proteasome to protect cells against the accumulation of oxidant-damaged proteins could be linked to its role in improving the generation of MHC class I ligands. It could be demonstrated that during a virus infection in non-immune cells the production of reactive oxygen species by the alternative NADPH oxidase Nox4 is of critical importance resulting in the accumulation of potentially toxic oxidant-damaged proteins. Indeed, within two hours of infection structural virus proteins were oxidized and subsequently poly-ubiquitylated. The concomitant formation of i-proteasomes led to a rapid and efficient degradation of ubiquitylated virus antigens thereby improving the liberation of immunodominant viral epitopes. In conclusion, a so far unknown mechanism to fuel proteasomal substrates into the MHC class I antigen presentation pathway has been revealed. A new protein pool consisting of exogenously delivered viral proteins provides proteasomal substrates in the very early phase of a virus infection. Within the scope of this thesis the i-proteasome has been shown to link the protection against oxidative stress, initiated directly by pathogen recognition, with the generation of antigenic peptides. Together, an effective adaptive immune response is triggered.

Für die Progression des Wachstums maligner Tumoren und ihre Metastasierung ist die Angiogenese, die Bildung neuer Blutgefäße aus bereits existierenden, eine essentielle Voraussetzung. In dieser Arbeit konnte gezeigt werden, dass die proangiogenen Transkriptionsfaktoren c-Jun, Id1 und Id3 in ihrer Stabilität gegenüber dem Ubiquitin/26S-Proteasom-System durch das COP9-Signalosom (CSN) kontrolliert werden. Dieses bildet einen multimeren Proteinkomplex, der deutliche Homologien mit dem Lid-Subkomplex des 26S-Proteasoms aufweist. Sowohl c-Jun als auch Id3 binden an die Untereinheit CSN5. Id3 interagiert zusätzlich mit CSN7. Rekombinantes c-Jun, ein bekanntes Substrat der CSN-assoziierten Kinasen CK2 und PKD, wird durch Curcumin, einen Hemmstoff dieser Kinasen, deutlich destabilisiert. Daneben induziert Curcumin hochmolekulare Formen von c-Jun, bei denen es sich höchstwahrscheinlich um Ubiquitin-Konjugate handelt. Ferner beschleunigt Curcumin, ebenso wie die CK2- und PKD-Inhibitoren Emdodin, DRB und Resveratrol, in HeLa-Zellen den proteasomalen Abbau von c-Jun. Die c-Jun-abhängige Produktion von VEGF wird durch alle vier Kinase-Hemmstoffe signifikant reduziert. Verstärkt wird dieser Effekt noch durch den proteasomalen Inhibitor MG-132. Id3 wird nicht von den CSN-assoziierten Kinasen phosphoryliert. Allerdings hemmt es in einem Kinase-Assay die Phosphorylierung von c-Jun, ICSBP und CSN2. Curcumin und Emodin regen in HeLa-Zellen die Ubiquitinierung und den proteasomalen Abbau von Id3 an. Die Proteolyse von Id1 wird in HeLa-Zellen ebenfalls in Anwesenheit dieser beiden Hemmstoffe stimuliert. Mittels Kotransfektion von Id3 und His-markiertem Ubiquitin konnte eine verstärkte Ubiquitinierung von Id3 in Gegenwart von Curcumin direkt nachgewiesen werden. Außerdem wird Id3 durch die Überexpression von CSN2 stabilisiert. Auf diesen Daten basiert die Schlussfolgerung, dass die CSN-abhängige Phosphorylierung den Abbau von c-Jun und der beiden Id-Proteine über das Ubiquitin/26S-Proteasom-System inhibiert und dadurch ein interessantes neues Ziel einer antiangiogenen Tumortherapie repräsentiert. / Angiogenesis, the formation of new blood vessels from the existing vasculature, is a prerequisite for the progression of solid tumor growth and metastasis. In this study it is shown that the COP9 signalosome (CSN) regulates the stability of the angiogenic transcription factors c-Jun, Id1 and Id3 towards the ubiquitin/26S proteasome system. The COP9 signalosome constitutes a multimeric protein complex that shares sequence homology with the 26S proteasome lid complex. Both c-Jun and Id3 physically interact with the CSN subunit CSN5. In addition, Id3 can bind to CSN7. Recombinant c-Jun, a substrate of the CSN-associated kinases CK2 und PKD, is destabilized by curcumin, an inhibitor of these two kinases. Furthermore, curcumin induces high molecular weight c-Jun species, most likely ubiquitin conjugates. All tested inhibitors of the CK2 and PKD, emodin, DRB, resveratrol, as well as curcumin accelerate the degradation of c-Jun by the 26S proteasome in HeLa cells. The c-Jun-dependent expression of VEGF, the most potent angiogenic factor, is significantly reduced by the four kinase inhibitors. MG-132, an inhibitor of the 26S proteasome, also diminishes the production of VEGF. Id3 is not phosphorylated by the CSN-associated kinases. However, it inhibits c-Jun, ICSBP and CSN2 phosphorylation. Curcumin and emodin significantly induce ubiquitination and proteasome-dependent degradation of Id3 in HeLa cells. Proteasome-dependent degradation Id1 in HeLa cells is also stimulated by treatment with curcumin or emodin. Ubiquitination of Id3 is shown directly by cotransfection of HeLa cells with Id3 and His-tagged ubiquitin. Curcumin increases Id3-ubiquitin conjugate formation. In addition, overexpression of CSN2 leads to stabilization of Id3 protein. On the basis of these data it is concluded that CSN-mediated phosphorylation inhibits ubiquitination and proteasome-dependent degradation of c-Jun, Id1 and Id3. The COP9 signalosome thus represents an interesting new target for antiangiogenic tumor therapy.

O fator CIITA é a proteína responsável por controlar a transcrição de genes do complexo principal de histocompatibilidade de classe II (MHC II) envolvidos na apresentação antigênica a linfócitos T CD4+. A expressão desta proteína é complexa e célula-específica, dependendo de mecanismos de regulação transcricionais e póstranscricionais. Com o intuito de investigar o potencial do fator CIITA como adjuvante molecular, no presente estudo desenvolvemos e validamos sistemas de transferência gênica capazes de promover a eficiente expressão de CIITA em vários tipos celulares. Além disso, investigamos a regulação pós-traducional deste fator em células não hematopoéticas. Desta forma, foram produzidos um vetor plasmidial e um vetor lentiviral, ambos carreando a sequência do fator CIITA humano desenhada in silico visando a eliminação de elementos cis-reguladores, e otimizada para eficiente expressão em células humanas. A transfecção/transdução de três linhagens de células humanas não hematopoéticas resultou na eficiente expressão de CIITA com localização nuclear apropriada. Células expressando CIITA apresentaram síntese de novo do MHC II, confirmando a funcionalidade da proteína e validando ambos os vetores para a análise futura da atividade adjuvante do CIITA em imunizações gênicas. Ensaios preliminares de inoculação de explantes de pele humana com o vetor lentiviral evidenciaram a eficiente transdução e expressão do CIITA exógeno em células primárias. Em seguida, células dendríticas (DCs) derivadas de monócitos de indivíduos saudáveis ou infectados com HIV-1 foram transduzidas com o vetor lentiviral para confirmar a expressão do CIITA em células primárias e avaliar a aplicação desse sistema adjuvante no aprimoramento da vacina de DCs anti-HIV. DCs de indivíduos saudáveis ou infectados foram transduzidas com sucesso pelo lentivírus, o qual induziu uma produção prolongada do mRNA codificando CIITA. Entretanto, os vetores lentivirais induziram um aumento inespecífico da expressão de marcadores fenotípicos das DCs, incluindo as moléculas do MHC II, o que impediu a avaliação indireta da expressão e atividade do fator CIITA através da detecção da expressão aumentada do MHC II. Ensaios futuros irão avaliar se o fator transcricional é expresso pelas DCs transduzidas ou se essas células apresentam um controle mais restrito da expressão do CIITA comparadas às linhagens celulares avaliadas. Interessantemente, ensaios de western blot comparativos entre as três linhagens de células humanas transfectadas/transduzidas, juntamente com ensaios de inibição da degradação protéica pelo inibidor do proteassoma, nos permitiu descrever um novo mecanismo de regulação pós-traducional do CIITA. Aqui, nós identificamos que cada tipo de célula não hematopoética mantém níveis específicos da proteína, e portanto, da sua atividade transcricional, através da regulação da degradação do CIITA pelo proteassoma. Essa regulação é mediada pela modulação dos níveis das proteínas da leucemia promielocítica (PML) acopladas a proteínas SUMO (modificadores pequenos similares à ubiquitina), modificação pós-traducional requerida para a interação PML-CIITA que impede a degradação pelo proteassoma. Esse novo mecanismo aqui descrito contribui para o entendimento ainda incipiente da regulação pós-traducional do fator CIITA em células não hematopoéticas e pode ter implicações importantes na aplicação dessa proteína como adjuvante molecular para imunoterapias / The CIITA factor is a protein responsible for controlling the transcription of major histocompatibility complex class II (MHC II) genes involved on antigen presentation to CD4+ T helper cells. The expression of this transcription factor is complex and differs in various cell types depending on transcriptional and post-transcriptional regulatory mechanisms. In order to investigate the CIITA factor potential as molecular adjuvant, here we developed and validated two gene delivery systems capable of promoting efficient CIITA expression in various human cell types. Additionally, we applied the delivery systems to investigate the post-translational regulation of this factor in nonimmune cells. A DNA plasmid and a lentiviral vector were produced, both carrying the human CIITA DNA sequence in silico designed to avoid cis-regulatory elements, and genetic optimized for expression efficacy in human cells. Transfection or transduction of three different non-immune human cell lines resulted in efficient CIITA expression with proper nuclear localization. The CIITA-expressing cells presented de novo MHC II molecules expression confirming the functionality of the exogenous protein, and validating both delivery systems for the future analysis of the CIITA adjuvant activity in genetic immunizations. Preliminary assays involving the inoculation of the lentiviral vector into human skin explants showed efficient transduction and expression of exogenous CIITA in primary cells. Next, monocyte-derived dendritic cells (DCs) from healthy individuals and HIV-1-infected patients were transduced with the lentiviral vector to confirm the exogenous CIITA expression in primary human cells and also evaluate the applicability of this adjuvant system to improve the DC-based vaccines against HIV. DCs from healthy and infected individuals were successfully transduced by the lentivirus, which induced a sustained CIITA mRNA production. However, the vector particles by themselves induced an unspecific upregulation of DC`s phenotypic surface markers, including the MHC II molecules, impairing our strategy to indirectly evaluate CIITA expression and activity through the detection of MHC II enhanced expression. Further investigations are necessary to confirm whether the transcription factor is efficiently expressed in transduced DCs or if these cells present a more restrict control of CIITA protein expression than the evaluated non-immune cells. Interestingly, western blot assays comparing the three human cell lines, transfected or transduced, along with inhibition of protein degradation by proteasome inhibitor treatments, allowed us to describe a new and intricate mechanism of CIITA post-translational regulation. Here we identified that each non-immune cell type maintain specific protein levels, and hence transcriptional activity, by modulating the rate of CIITA proteasomal degradation. This modulation is achieved by controlling the levels of Promyelocytic Leukemia (PML) proteins attached to Small Ubiquitin-like Modifier (SUMO) proteins, a post-translational modification required for the PML-CIITA interaction, which impairs the proteasomal degradation. This new mechanism described here contributes to the developing understanding of the CIITA post-translational regulation in non-immune cells, and might have important implications in the use of this transcription factor as a molecular adjuvant for immunotherapies

Metazoans have evolved conserved mechanisms to promote cell survival under low oxygen tensions by initiating a transcriptional cascade centered on the action of Hypoxia Inducible transcription Factors (HIFs). In aerobic conditions, HIFs are inactivated by ubiquitin-proteasome-mediated degradation of their a subunit, which is dependent on prolyl hydroxylation by 2-oxoglutarate (2-OG) and Fe(II)-dependent prolyl hydroxylases (PHDs). In hypoxia, HIF-$\alpha$ is no longer hydroxylated and is therefore stabilised, activating a global transcriptional response to ensure cell survival. Interestingly, HIFs can also be activated in aerobic conditions, however the mechanisms of this oxygen-independent regulation are poorly understood. Here, I have explored the role of the vacuolar H+-ATPase (V-ATPase), the major proton pump for acidifying intracellular vesicles and facilitating lysosomal degradation, in regulating HIF-$\alpha$ turnover. Unbiased forward genetic screens in near-haploid human cells identified that disruption of the V-ATPase leads to activation of HIFs in aerobic conditions. Rather than preventing the lysosomal degradation of HIF-$\alpha$, I found that V-ATPase inhibition indirectly affects the canonical proteasome-mediated degradation of HIF-$\alpha$ isoforms by altering the intracellular iron pool and preventing HIF-$\alpha$ prolyl hydroxylation. In parallel, I characterised two putative mammalian V-ATPase assembly proteins, TMEM199 and CCDC115, identified by the forward genetic screen and subsequent mass spectrometry analysis. I confirmed that both TMEM199 and CCDC115 are required for V-ATPase function, and established assays to determine how TMEM199 and CCDC115 associate with components of the core V-ATPase complex. Lastly, to measure how V-ATPase activity leads to changes in the labile iron pool, I developed an endogenous iron reporter using CRISPR-Cas9 knock-in technology. This approach confirmed that iron homeostasis is impaired during V-ATPase inhibition, and demonstrated that exogenous ferric iron can restore the labile iron pool in a transferrin-independent manner. Together my studies highlight a crucial link between V-ATPase activity, iron homeostasis, and the hypoxic response pathway.

No description available.

No description available.

A recent model of Parkinson’s disease (PD) suggests that the neuropathological, behavioural and cognitive symptoms progress in stages. There is substantial evidence for a prodromal stage of PD, during which time pre-motor symptoms develop. Rapid eye movement (REM) sleep behaviour disorder (RBD) is a risk factor for developing PD and may be part of the pre-motor stage. In both disorders, neuropathological α-synuclein aggregates are thought to be a direct cause of the resulting symptoms. One model has shown that in rats, proteasome inhibition produced by systemic exposure to environmental toxins results in α-synuclein pathology and motor behaviour dysfunction that mimics the progression of PD in humans. The present study examined the hypothesis that the systemic proteasome inhibition model would produce pre-Parkinsonian RBD-like pathology in rats. It was expected that sleep disturbances would be seen prior to behavioural disturbances in rats treated systemically with PSI (a proteasome inhibitor). Following baseline sleep recording and training on the inclined beam-traverse task, rats were injected with PSI (a proteasome inhibitor) or ethanol (control), 6 times over 2 wk. Sleep recording over 8 wk and behavioural testing over 16 wk provided no evidence of sleep disturbances or motor dysfunction. Post-mortem immunohistochemical analyses of brain tissue provided no evidence of PSI-associated α-synuclein aggregates in the locus coeruleus, subcoeruleus (dorsal part), or substantia nigra (areas involved in RBD and/or PD). These results did not provide support for RBD as a prodromal phase of PD within the systemic proteasome inhibitor-based model and add to a growing body of research reporting inconsistent findings using this model. We suggest that systemic PSI exposure in rats does not produce a viable model of RBD or PD. Whether RBD is an early symptom in the progression of PD remains to be established. / Thesis (Master, Neuroscience Studies) -- Queen's University, 2010-04-28 12:04:50.613

Les estrogènes jouent un rôle primordial dans le développement et le fonctionnement des tissus reproducteurs par leurs interactions avec les récepteurs des estrogènes ERα et ERβ. Ces récepteurs nucléaires agissent comme facteurs de transcription et contrôlent l’expression des gènes de façon hormono-dépendante et indépendante grâce à leurs deux domaines d’activation (AF-1 et AF-2). Une dérégulation de leur activité transcriptionnelle est souvent à l’origine de pathologies telles que le cancer du sein, de l’endomètre et des ovaires. Alors que ERα est utilisé comme facteur pronostic pour l’utilisation d’agents thérapeutiques, l’importance de la valeur clinique de ERβ est encore controversée. Toutefois, des évidences récentes lui associent un pouvoir anti-tumorigénique en démontrant que sa présence favorise l’inhibition de la progression de ces cancers ainsi que l’efficacité des traitements. En combinaisons avec d’autres études, ces observations démontrent que bien que les deux isoformes partagent une certaine similitude d’action, les ERs sont en mesure d’exercer des fonctions distinctes. Ces différences sont fortement attribuables au faible degré d’homologie observé entre certains domaines structuraux des ERs, comme le domaine AF-1, ce qui fait en sorte que les différents sites de modifications post-traductionnelles (MPTs) présents sur les ERs sont très peu conservés entre les isoformes. Or, l’activité transcriptionnelle ligand-dépendante et indépendante des ERs est hautement régulée par les MPTs. Elles sont impliquées à tous les niveaux de l’activation des ERs incluant la liaison et la sensibilité au ligand, la localisation cellulaire, la dimérisation, l’interaction avec l’ADN, le recrutement de corégulateurs transcriptionnels, la stabilité et l’arrêt de la transcription. Ainsi, de par leur dissimilitude, les ERs seront différemment régulés par la signalisation cellulaire. Comme un débalancement de plusieurs voies de signalisation ont été associées à la progression de tumeurs ER-positives ainsi qu’au développement d’une résistance, une meilleure compréhension de l’impact des MPTs sur la régulation spécifique des ERs s’avère essentielle en vue de proposer et/ou développer des traitements adéquats pour les cancers gynécologiques. Les résultats présentés dans cette thèse ont pour objectif de mieux comprendre les rôles des MPTs sur l’activité transcriptionnelle de ERβ qui sont, contrairement à ERα, très peu connus. Nous démontrons une régulation dynamique de ERβ par la phosphorylation, l’ubiquitination et la sumoylation. De plus, toutes les MPTs nouvellement découvertes par mes recherches se situent dans l’AF-1 de ERβ et permettent de mieux comprendre le rôle capital joué par ce domaine dans la régulation de l’activité ligand-dépendante et indépendante du récepteur. Dans la première étude, nous observons qu’en réponse aux MAPK, l’AF-1 de ERβ est phosphorylé au niveau de sérines spécifiques et qu’elles jouent un rôle important dans la régulation de l’activité ligand-indépendante de ERβ par la voie ubiquitine-protéasome. En effet, la phosphorylation de ces sérines régule le cycle d’activation-dégradation de ERβ en modulant son ubiquitination, sa mobilité nucléaire et sa stabilité en favorisant le recrutement de l’ubiquitine ligase E6-AP. De plus, ce mécanisme d’action semble être derrière la régulation différentielle de l’activité de ERα et ERβ observée lors de l’inhibition du protéasome. Dans le second papier, nous démontrons que l’activité et la stabilité de ERβ en présence d’estrogène sont étroitement régulées par la sumoylation phosphorylation-dépendante de l’AF-1, processus hautement favorisé par l’action de la kinase GSK-3. La sumoylation de ERβ par SUMO-1 prévient la dégradation du récepteur en entrant en compétition avec l’ubiquitination au niveau du même site accepteur. De plus, contrairement à ERα, SUMO-1 réprime l’activité de ERβ en altérant son interaction avec l’ADN et l’expression de ses gènes cibles dans les cellules de cancers du sein. Également, ces recherches ont permis d’identifier un motif de sumoylation dépendant de la phosphorylation (pSuM) jusqu’à lors inconnu de la communauté scientifique, offrant ainsi un outil supplémentaire à la prédiction de nouveau substrat de la sumoylation. En plus de permettre une meilleure compréhension du rôle des signaux intracellulaires dans la régulation de l’activité transcriptionnelle de ERβ, nos résultats soulignent l’importance des MPTs dans l’induction des différences fonctionnelles observées entre ERα et ERβ et apportent des pistes supplémentaires à la compréhension de leurs rôles physiopathologiques respectifs. / Estrogens play a pivotal role in reproductive physiology through direct interaction with the estrogen receptors ERα and ERβ, which belong to the nuclear hormone receptor family of ligand-activated transcription factors. Harbouring two activation domains (AF-1 and AF-2), gene expression can be controlled by ERs either in a hormone-dependent and/or independent manner. Disruption of ER transcriptional regulation is associated with pathological events such as breast and endometrial cancers. While ERα is considered a strong predictive factor in endocrine therapy of reproductive cancers, the clinical value of ERβ is still debated, although greater expression of ERβ has been associated with a favourable outcome since recent evidence has associated ERβ with anti-tumorigenic properties and a better response to anti-estrogenic compounds. Along with others studies, those individual outcomes indicate that even though the two receptors can exert similar roles by sharing resemblances in terms of structure and general response to hormone, they can also carry out distinct functions. These variations can be attributed to the fact that most of the structural domains shared by ERs exhibit a low level of homology, especially at the AF-1 domain. Consequently, the majority of the post-translational modifications sites (PTMs) on ERs are not shared between both isoforms. In fact, ligand-induced and ligand-independent activities of ERs are critically influenced by PTMs. PTMs controls the multiple aspects of ER-dependent activation by modulating ERs ligand binding, specificity, cellular localization, dimerization, interaction with their cognate DNA response element, combinatory recruitment of transcriptional coregulators, stability and transcriptional arrest. Hence, by their discrepancies, ERs will be differently influenced by the cellular environment. Furthermore, as the deregulation of different signalling pathway in cancers is associated with ER-dependant tumour progression and in the acquisition of a therapeutic resistant phenotype, it is crucial to understand the how PTMs affect ERs transactivation in order to eventually propose and/or develop adequate treatment. The results presented in this thesis were carried out with the objective of gaining a better understanding of PTM’s roles on ERβ transcriptional control which, as opposed to ERα, remain unclear. We demonstrate here a dynamic regulation of ERβ by phosphorylation, ubiquitination and sumoylation. Furthermore, as all the newly identified PTM are located within de AF-1 domain of ERβ, our results highlight the key role of this domain in the regulation of ligand-dependent and independent transcriptional properties of this receptor. The first study shows that in response to MAPK, specific serine residues in the AF-1 of ERβ are phosphorylated and play an important role in the regulation of ERβ ligand-independent activity by the ubiquitin-proteasome pathway. In fact, the activation-degradation cycle of ERβ induced by MAPK is regulated upon phosphorylation of these serines coordinating ERβ ubiquitination, subnuclear mobility and stability by promoting the recruitment of the ubiquitin ligase E6-AP. Moreover, this molecular process plays part in the differential regulation of ERα and ERβ activity upon proteasome inhibition. In the second paper, we demonstrate that ERβ activity and stability in presence of estrogen is closely regulated by the phosphorylation-dependent sumoylation of the AF-1 domain, amplified by GSK-3 action. SUMO-1 attachment prevents ERβ degradation by competing with ubiquitin at the same acceptor site and dictates ERβ transcriptional inhibition, as opposed to ERα, by altering estrogen-responsive target promoter occupancy and gene expression in breast cancer cells. Furthermore, these findings uncover a novel phosphorylated sumoylation motif (pSuM) and offer a valuable tool to predict novel SUMO substrates under protein kinase regulation. In combination to our better understanding on how intracellular signals controls ERβ transcriptional activity, our results highlight the significant role of PTMs in ERs isoforms discrepancies and allows supplementary comprehension of their respective physiopathologicals roles.

Les papillomavirus sont de petits virus à ADN double brin qui infectent les cellules de l’épithélium de la peau et des muqueuses d’une variété de vertébrés causant des lésions bénignes telles des verrues. Certains de ces virus sont également associés au développement de lésions malignes, notamment le cancer du col utérin. La protéine régulatrice E2 des papillomavirus est impliquée dans diverses fonctions contribuant à l’établissement de l’infection par ces virus. Entre autre, E2 régule la transcription des gènes viraux, participe à l’initiation de la réplication de l’ADN viral en s’associant à l’hélicase virale E1 et est responsable du maintien et de la ségrégation de l’épisome viral au cours de la division cellulaire. Toutes ces activités sont attribuables à la capacité de E2 à s’associer au génome viral et à interagir avec des protéines virales et cellulaires. De plus, ces fonctions sont elles-mêmes régulées par des modifications post-traductionnelles de la protéine E2. Plusieurs études ont été réalisées afin de découvrir les mécanismes de régulation des fonctions de E2 mais le rôle exact des différents domaines de E2 dans ces contrôles reste à être défini. En premier lieu, nous nous sommes intéressés à l’interaction entre E2 et Brd4(L) qui avait été définie comme étant essentielle à la ségrégation de l’épisome. Plusieurs caractéristiques associées à la protéine Brd4(L) telles que sa capacité à lier les lysines acétylées des histones, son interaction avec le complexe Mediator et sa participation à l’activation de la transcription en formant un complexe avec pTEFb, nous ont permis d’émettre l’hypothèse que l’interaction E2-Brd4(L) est nécessaire à l’activité transcriptionnelle de E2. Nous avons démontré que la protéine Brd4(L) interagit avec le domaine de transactivation de E2 de divers types de papillomavirus. De plus, cette interaction implique les résidus de E2 essentiels à son activité transcriptionnelle. Ainsi, ces résultats proposent que l’association E2-Brd4(L) serve à la régulation de la transcription des gènes viraux. Dans un second temps, nos recherches se sont concentrées sur l’existence d’une interface de dimérisation au sein du domaine de transactivation de E2 et de son implication dans les activités transcriptionnelles et réplicatives de la protéine. Nos études ont aussi mis en évidence que l’intégrité de la structure de ce domaine contribue au bon fonctionnement de la réplication du génome viral. Cette découverte suggère que la dimérisation de E2 peut réguler l’initiation de la réplication et propose l’existence d’un niveau de régulation additionnel impliquant l’état de la structure quaternaire de la protéine E2 et une modulation de l’interaction entre E1 et E2 à cette étape du cycle viral. Finalement, l’étude de l’instabilité de la protéine E2 nous a permis de définir une région importante dans le domaine flexible de la protéine, nécessaire à sa dégradation par le protéasome. De plus, la présence de résidus conservés localisés dans ce domaine, sont associés à la dégradation et portent la signature d’un signal de localisation nucléaire de type PY-NLS, suggérant que la stabilité de la protéine E2 est régulée par sa localisation au sein de la cellule. Ces études démontrent l’existence de nouvelles stratégies de régulation des activités transcriptionnelle et réplicative de la protéine E2 des papillomavirus. La compréhension de ces mécanismes nous permet de mieux cerner les étapes favorisant l’établissement et la progression du cycle viral et d’identifier de nouvelles cibles thérapeutiques contre les infections aux papillomavirus. / Papillomaviridae is a family of small double-stranded DNA viruses known as papillomaviruses (PV) which infect skin and mucosal epithelial cells where they cause benign lesions such as warts. A subset of these viruses is associated with the development of malignant lesions and is the causal agent of cervical cancer. Papillomavirus E2 regulatory protein is involved in several functions leading to the establishment of the viral infection. These activities include the regulation of viral genes transcription, it participation to the initiation of viral DNA replication by recruiting the viral helicase E1, and to the maintenance and segregation of the viral episome during cellular division. All these functions are associated to the ability of E2 to bind specifically the viral genome, to interact with viral and cellular proteins and to acquire post-translational modifications. The first article of this thesis led to the identification of Brd4(L) as the major protein associated to E2 protein of different papillomavirus types. This interaction involves the amino acids associate to the transcription function of E2. The protein Brd4(L) was identified originally as a factor that maintains epigenetic memory by it interaction with acetylated histones during mitosis. This association with the chromatin, it interaction with Mediator complex and it participation to the cellular transcription by recruiting pTEFb complex allowed us to propose that the interaction between Brd4 and E2 is essential to the regulation of viral gene transcription. The second part of this work based on previous characterization of the transactivation domain dimerization interface; investigate the role of this surface in the transcriptional and replicative activities of E2. Our studies demonstrated that the integrity of the TAD dimerization interface may contribute to the DNA replication activity of E2. This discovery suggests that the dimerization interface may regulate the viral DNA replication by the redox state of the E2 protein. A fine characterization of this interface may provide new aspect of the interaction between E1 and E2 in the context of viral cycle. Finally, the third section of this thesis define a region of E2 protein associated to it degradation by the proteasome. This study also demonstrates that the stability of E2 is related to its cellular localization and suggests that the highly conserved residues found in this region may represent a PY-NLS nuclear localization signal signature. This thesis shows the existence of different approaches to regulate the transcriptional and the replicative activities as well as the stability of the papillomavirus E2 protein to favor the establishment and the progression of viral cycle.